Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium alginate silver is a wound dressing composed of calcium alginate fibers integrated with silver (typically as nanoparticles or ions). The product leverages the high absorbency and gel-forming properties of calcium alginate to manage exudate and maintain a moist wound environment. Silver provides broad-spectrum antimicrobial activity by releasing silver ions that disrupt bacterial cell membranes and metabolic processes. This combination is used for moderate to heavily exuding wounds at risk of infection or already infected—including pressure ulcers, diabetic foot ulcers, venous leg ulcers, surgical wounds, traumatic injuries (cuts/abrasions), burns (including second-degree), donor sites after skin grafts, and cavity wounds. The dressing also promotes hemostasis via ion exchange between calcium in the fibers and sodium in wound exudate[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium alginate silver.